MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.39
+0.09
+1.60%
Opening 09:52 01/25 EST
OPEN
5.35
PREV CLOSE
5.30
HIGH
5.40
LOW
5.29
VOLUME
42.81K
TURNOVER
--
52 WEEK HIGH
17.95
52 WEEK LOW
3.800
MARKET CAP
169.99M
P/E (TTM)
-5.2773
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
At 7% CAGR, Mesenchymal Stem Cells Market Size, Share and Analysis remuneration to reach $ 2,518.5 Million by 2026
Jan 25, 2021 (Market Insight Reports) -- Selbyville, Delaware. The report Mesenchymal Stem Cells Market Size and Analysis maintains enhanced dynamics and is...
Market Insight Reports · 1h ago
Autologous Cell Therapy Market Size is Projected to Showcase Significant Growth Over 2027
Jan 25, 2021 (Market Insight Reports) -- The global Autologous Cell Therapy market is expected to reach nearly US$ 34.6 Bn by the end of 2027, reflecting a...
Market Insight Reports · 4h ago
Outlook on the Mesenchymal Stem Cells Global Market to 2021-2026 Impact Analysis of COVID-19
Market Insight Reports · 4d ago
BRIEF-Brainstorm Announces Publication Of Preclinical Data Highlighting Potential Of COVID-19 ARDS Treatment
reuters.com · 5d ago
BrainStorm Cell Therapeutics Highlights Publication Of Preclinical Data Showing Potential Of NurOwn Derived Exosome-Based Treatment For COVID-19 Acute Respiratory Distress Syndrome
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem
Benzinga · 5d ago
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS
, /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the of a preclinical study in the journal . The study, entitled "MSC-NTF (NurOwn®) exosom...
PR Newswire - PRF · 5d ago
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS
NEW YORK, Jan. 20, 2021 /PRNewswire via COMTEX/ -- NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading...
PR Newswire - PRF · 5d ago
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy. The study...
PR Newswire · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCLI. Analyze the recent business situations of Brainstorm Cell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCLI stock price target is 29.00 with a high estimate of 33.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 7.32M
% Owned: 23.20%
Shares Outstanding: 31.57M
TypeInstitutionsShares
Increased
27
582.88K
New
30
265.77K
Decreased
16
283.79K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.19%
Pharmaceuticals & Medical Research
+0.34%
Key Executives
Chairman/Director
Jacob Frenkel
President
Ralph Kern
Chief Executive Officer
Chaim Lebovits
Vice Chairman/Director
Irit Arbel
Chief Financial Officer/Executive Vice President/Treasurer
Preetam Shah
Chief Operating Officer/Executive Vice President
David Setboun
Executive Vice President/Director
Uri Yablonka
Executive Vice President
Stacy Lindborg
Executive Vice President
Anthony Waclawski
Other
Arturo Araya
Director
Sankesh Abbhi
Independent Director
June Almenoff
Independent Director
Anthony Polverino
Independent Director
Malcolm Taub
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
More

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.